Immunocore to present at upcoming investor conferences
30 Octubre 2023 - 2:30PM
Immunocore to present at upcoming
investor conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 30 October 2023) Immunocore Holdings Plc
(Nasdaq: IMCR), a commercial-stage biotechnology company pioneering
the development of a novel class of T cell receptor (TCR)
bispecific immunotherapies designed to treat a broad range of
diseases, including cancer, infectious diseases and autoimmune
conditions, today announced that management will present at the
following investor conferences in November:
- TD Cowen Fall Oncology
Innovation Summit: Insights for SITC and ASHFireside Chat:
Friday, November 3, 2023, at 2:20 p.m. EDT
- Truist Securities BioPharma
Symposium 1x1 and small group meetings: Wednesday,
November 8, 2023
- Jefferies London Healthcare
Conference Fireside Chat: Tuesday, November 14, 2023, at
2:30 p.m. GMT
-
3rd Annual BTIG
Ophthalmology DayFireside Chat: Monday, November 27, 2023,
at 10:30 a.m. EST
Where relevant, the presentations will be webcast live and can
be accessed by visiting ‘Events’, under ‘News & Events’, via
the ‘Investors’ section of Immunocore’s website at
www.immunocore.com. Following the events, a replay of the
presentations will be made available for a limited time.
##
About Immunocore
Immunocore is a commercial-stage biotechnology
company pioneering the development of a novel class of TCR
bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including four clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been
approved for the treatment of HLA-A*02:01-positive adult patients
with unresectable or metastatic uveal melanoma in the United
States, European Union, Canada, Australia, and the United
Kingdom.
CONTACT:
Immunocore Sébastien Desprez, Head of
CommunicationsT: +44 (0) 7458030732E:
sebastien.desprez@immunocore.comFollow on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor RelationsT: +1 215-384-4781E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immunocore (NASDAQ:IMCR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024